• 5241 Citations
  • 38 h-Index
1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

After obtaining his MD and PhD degrees, Dr. Zu attended the University of Connecticut Health Center as a postdoctoral fellow and later remained there as an assistant professor. He then spent four years in pathology residency training at New York University, followed by a two-year hematopathology fellowship at the National Cancer Institute of the National Institutes of Health. Dr. Zu joined the Department of Pathology and Genomic Medicine at Houston Methodist Hospital in 2004, where he currently serves as the Medical Director of the Hematopathology Section. He is also Professor of Pathology and Laboratory Medicine at the Weill Cornell Medical College of Cornell University. In addition to his clinical responsibilities, Dr. Zu is also the Director of the Cancer Pathology research laboratory at the Houston Methodist Research Institute. These combined positions enable him to address clinically-driven questions. As a physician-scientist, Dr. Zu has pioneered the translation of the oligonucleotide aptamers and nanotechnology into clinical applications, and his research is currently funded by multiple NIH and CPRIT grants.

Research interests

Dr. Zu's clinical interests include diagnosis of hematopoietic and lymphoid disorders. His research centers on the development of novel diagnostics and treatments for these disorders. His laboratory was the first to use aptamer probes to enhance the diagnostic capabilities of multi-color flow cytometry amd immunohistochemical staining, and for rapid detection of circulating tumor cells in whole blood samples. By combining nanotechnology with aptamer technology, Dr. Zu's laboratory is also developing new multi-functional nanomedicine for specific tumor imaging and targeted therapy of several cancer types, including lymphomas, multiple myeloma, pancreatic cancer, breast cancer, prostate cancer, ovarian cancer, and hepatocellular (liver) carcinoma. Other directions of his laboratory include studies on the role of cancer stem cells in the development of multiple myeloma and elucidating the molecular mechanisms underlying the myelodysplastic syndrome.

Education/Academic qualification

Hematopathology, Clinical Fellowship, National Cancer Institute (NCI)

Jul 1 2002Jun 30 2004

Award Date: Jun 30 2004

Pathology, Residency, New York University Medical Center

Jul 1 1998Jun 30 2002

Award Date: Jun 30 2002

Postdoctoral Fellowship, University of Connecticut Health Center

Jul 1 1992Jun 30 1998

Award Date: Jun 30 1998

Postdoctoral Fellowship, Tsukuba Life Science Research Center, RIKEN

Feb 1 1990Jun 30 1992

Award Date: Jun 30 1992

PhD, Kyoto University Graduate School of Medicine

Oct 1985Jan 1 1990

Award Date: Jan 1 1990

MD, Jilin Medical College

Apr 1 1978Dec 1 1982

Award Date: Dec 1 1982

Research Area Keywords

  • Precision Medicine
  • Cancer
  • Nanomedicine
  • Infectious Disease & Pathology

Free-text keywords

  • Aptamer technology

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

  • 5241 Citations
  • 38 h-Index
  • 113 Article
  • 10 Review article
  • 2 Comment/debate
  • 1 Chapter (peer-reviewed)

Aptamer cocktail to detect multiple species of mycoplasma in cell culture

Wan, Q., Liu, X., Zeng, Z., Chen, Z., Liu, Y. & Zu, Y., Jun 1 2020, In : International journal of molecular sciences. 21, 11, 3784.

Research output: Contribution to journalArticle

  • 1 Scopus citations

    Aptamer-equipped protamine nanomedicine for precision lymphoma therapy

    Zeng, Z., Tung, C. H. & Zu, Y., Apr 2020, In : Cancers. 12, 4, 780.

    Research output: Contribution to journalArticle

  • 1 Scopus citations
  • Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein

    Kourentzi, K., Crum, M., Patil, U., Prebisch, A., Chavan, D., Vu, B., Zeng, Z., Litvinov, D., Zu, Y. & Willson, R. C., Dec 1 2020, In : Scientific Reports. 10, 1, 5078.

    Research output: Contribution to journalArticle

  • T-cell lymphoma secondary to checkpoint inhibitor therapy

    Anand, K., Ensor, Jr., J. E., Pingali, S. R., Hwu, P., Duvic, M., Chiang, S., Miranda, R., Zu, Y. & Iyer, S., Feb 28 2020, In : Journal for immunotherapy of cancer. 8, 1, e000104.

    Research output: Contribution to journalArticle